B Group, Inc. has significantly increased its stake in ADMA Biologics, acquiring 750,000 shares valued at approximately $11.84 million, according to a May 15, 2026, SEC filing. Following this transaction, ADMA now represents 21.43% of B Group’s 13F assets under management, totaling 3,207,542 shares worth $28.90 million. Despite this acquisition, ADMA’s stock has struggled, down nearly 58% over the past year, contrasting sharply with the S&P 500’s 27% gain in the same period.
The increased investment comes amid mixed signals from ADMA’s financial performance. While first-quarter revenue remained flat at $114.5 million, adjusted net income rose by 22%, and ASCENIV sales surged by 28%. These results suggest potential for recovery, even as the company faces challenges in its BIVIGAM product line. B Group’s move indicates a belief in ADMA’s long-term value, despite recent pricing pressures in the immunoglobulin market.
For market professionals, this transaction highlights a potential buying opportunity in ADMA, especially given the company’s improving margins and cash flow, suggesting that B Group anticipates a rebound in performance.
Source: fool.com